|Bid||1.0000 x 1800|
|Ask||4.6500 x 1400|
|Day's Range||4.2200 - 4.2789|
|52 Week Range||3.7800 - 9.2500|
|Beta (3Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Yahoo Finance's Seana Smith and Adam Shapiro talks to Vered Caplan, CEO of Orgenesis, about making it to the top in a male-dominated field, and how her company is making a name for itself in the world of biotechnology.
Orgenesis Inc. shares soared 19% in premarket trade Monday, after the U.S. Food and Drug Administration granted Orphan Drug Designation to the company's Autologous Insulin Producing cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy, caused by chronic pancreatitis. Orgenesis has an exclusive license for the technology from Israel's Tel Hashomer Medical Research Infrastructure and Services Ltd., that is based on the work of Professor Sarah Ferber, the company's chief scientific officer and a researcher at THM. Patients who have total pancreatectomy always suffer from diabetes, which results in lifelong insulin-dependence with the loss of endogenous insulin secretion and that of the counter-regulatory hormone, glucagon. Shares have fallen 8% in 2019, while the S&P 500 has gained 15%.
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of Orgenesis Inc. (NASDAQ:ORGS) have suffered share price declines over the last year. The share price is down a...
Orgenesis Inc. (ORGS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In 2013 Vered Caplan was appointed CEO of Orgenesis Inc. (NASDAQ:ORGS). First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider theRead More...
If you own shares in Orgenesis Inc (NASDAQ:ORGS) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...